These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21732754)

  • 1. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
    Dancey JE; Monzon J
    Future Oncol; 2011 Jul; 7(7):827-39. PubMed ID: 21732754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
    Mita MM; Gong J; Chawla SP
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ridaforolimus.
    Drugs R D; 2010; 10(3):165-78. PubMed ID: 20945947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
    Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
    J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
    Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
    J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
    Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current phase II clinical data for ridaforolimus in cancer.
    Spreafico A; Mackay HJ
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1485-93. PubMed ID: 23964772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
    Mita MM; Poplin E; Britten CD; Tap WD; Rubin EH; Scott BB; Berk L; Rivera VM; Loewy JW; Dodion P; Haluska F; Sarantopoulos J; Mita A; Tolcher A
    Ann Oncol; 2013 Apr; 24(4):1104-11. PubMed ID: 23211938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
    Pearson AD; Federico SM; Aerts I; Hargrave DR; DuBois SG; Iannone R; Geschwindt RD; Wang R; Haluska FG; Trippett TM; Geoerger B
    Oncotarget; 2016 Dec; 7(51):84736-84747. PubMed ID: 27713169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.
    Gore L; Trippett TM; Katzenstein HM; Boklan J; Narendran A; Smith A; Macy ME; Rolla K; ; Narashimhan N; Squillace RM; Turner CD; Haluska FG; Nieder M
    Clin Cancer Res; 2013 Jul; 19(13):3649-58. PubMed ID: 23659969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.
    Chmielowski B; Federman N; Tap WD
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1217-28. PubMed ID: 23098121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for maintenance therapy in managing sarcoma.
    Ray-Coquard I; Le Cesne A
    Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.
    Frappaz D; Federico SM; Pearson AD; Gore L; Macy ME; DuBois SG; Aerts I; Iannone R; Geschwindt R; Van Schanke A; Wang R; Geoerger B
    Eur J Cancer; 2016 Jul; 62():9-17. PubMed ID: 27185573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
    Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
    J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.
    Elit L
    IDrugs; 2006 Sep; 9(9):636-44. PubMed ID: 16952072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Józwiak S; Stein K; Kotulska K
    Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
    Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
    J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models.
    Squillace RM; Miller D; Cookson M; Wardwell SD; Moran L; Clapham D; Wang F; Clackson T; Rivera VM
    Mol Cancer Ther; 2011 Oct; 10(10):1959-68. PubMed ID: 21825008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
    Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.